Muthiah Manoharan

• Leveraging advanced chemical modifications to develop novel conjugate platforms, to enable delivery beyond the liver with high specificity, to expand treatable diseases to include neurological disorders and rare cancers
• Applying bespoke chemical modifications to peptide-based and other conjugate systems to improve endosomal escape and intracellular siRNA bioavailability to boost gene silencing efficacy while reducing dose frequency and toxicity
• Implementing a next-generation, data-rich platform for the rapid design and optimization of novel ligand-siRNA chemistries to accelerate optimization of delivery chemistries for unmet clinical needs, for future-proofing Alnylam’s pipeline against GalNAc’s limitations

The future of RNAi lies at the intersection of precision medicine, AI-driven innovation, and strategic combination approaches. This panel explores how integrating cutting-edge technologies like AI target discovery with synergistic modalities can unlock new therapeutic potential. Experts will discuss multi-target silencing strategies, new target molecule classes, and how to future-proof RNAi pipelines to lead the next wave of transformative treatments. Join us to gain actionable insights on positioning your RNAi therapeutics at the forefront of precision medicine by discussing:

• Exploring AI-driven target discovery and combination therapies with CAR-T or radiotherapy to accelerate identification of disease-specific genes with high clinical relevance to enable faster precision RNAi therapy development
• Predicting future combination therapy strategies to stay ahead of emerging trends in multi-target silencing, for the expansion of treatment options for complex diseases
• Strategizing how to position pipelines at the forefront of next-gen RNAi innovation